CCLA Investment Management Buys 8,985 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

CCLA Investment Management increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 258,571 shares of the medical research company's stock after acquiring an additional 8,985 shares during the period. Thermo Fisher Scientific comprises about 2.1% of CCLA Investment Management's investment portfolio, making the stock its 19th biggest position. CCLA Investment Management owned 0.07% of Thermo Fisher Scientific worth $134,498,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in TMO. Community Trust & Investment Co. grew its stake in shares of Thermo Fisher Scientific by 2.2% in the 4th quarter. Community Trust & Investment Co. now owns 33,388 shares of the medical research company's stock valued at $17,369,000 after purchasing an additional 714 shares during the period. R.H. Investment Group LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter valued at $4,632,000. Pines Wealth Management LLC acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $1,309,000. SeaCrest Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 26.7% in the 4th quarter. SeaCrest Wealth Management LLC now owns 1,743 shares of the medical research company's stock valued at $907,000 after purchasing an additional 367 shares in the last quarter. Finally, Breakwater Capital Group grew its holdings in shares of Thermo Fisher Scientific by 8.8% in the 4th quarter. Breakwater Capital Group now owns 653 shares of the medical research company's stock worth $340,000 after purchasing an additional 53 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Up 0.1 %

TMO traded up $0.38 during midday trading on Wednesday, reaching $557.37. 643,695 shares of the company were exchanged, compared to its average volume of 1,882,372. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The stock has a market capitalization of $213.19 billion, a P/E ratio of 34.94, a PEG ratio of 3.54 and a beta of 0.76. The stock's 50-day simple moving average is $529.85 and its 200 day simple moving average is $568.13. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion for the quarter, compared to analysts' expectations of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company's revenue for the quarter was up .2% on a year-over-year basis. During the same period in the previous year, the firm posted $5.69 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock repurchase plan on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to buy up to 2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's board of directors believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.78%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the business's stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now owns 12,736 shares of the company's stock, valued at $7,134,197.76. The trade was a 13.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the sale, the executive vice president now directly owns 16,663 shares of the company's stock, valued at approximately $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,150 shares of company stock worth $25,954,465 in the last 90 days. Corporate insiders own 0.34% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on TMO shares. Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Royal Bank of Canada decreased their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Scotiabank began coverage on Thermo Fisher Scientific in a research report on Monday, December 23rd. They issued a "sector perform" rating and a $605.00 price objective for the company. Evercore ISI decreased their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. Finally, Barclays reduced their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating on the stock in a research report on Wednesday, October 23rd. Four investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $648.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.